The Appeal of a Simple Label
"Dysbiosis" has become one of the most widely used — and misused — terms in health communication. Broadly defined as an imbalance in the composition or function of the gut microbial community, it appears in thousands of published papers, wellness blogs, and supplement marketing materials. The concept is intuitive: a healthy microbiome is balanced; a diseased one is not. But this simplicity conceals significant scientific complexity.
What the Research Actually Shows
Studies consistently document microbial differences between healthy individuals and those with conditions such as IBD, IBS, obesity, type 2 diabetes, and colorectal cancer. Common findings include reduced alpha diversity (fewer species), decreased abundance of butyrate-producing Firmicutes (e.g., Faecalibacterium prausnitzii), and increased proportions of Proteobacteria (e.g., Escherichia coli). These associations are reproducible across multiple cohorts and sequencing platforms.
However, association is not causation. In IBD, intestinal inflammation itself reshapes the microbial environment — oxygen exposure from mucosal damage favours facultative anaerobes over obligate anaerobes. The observed "dysbiosis" may be a consequence of disease rather than its cause. Disentangling cause from effect remains one of the most challenging problems in microbiome science.
No Universal Definition
A fundamental limitation is that there is no consensus definition of a "healthy" microbiome against which dysbiosis can be measured. Microbial composition varies enormously between individuals, populations, geographies, and age groups. The Human Microbiome Project and MetaHIT consortium demonstrated that two perfectly healthy adults can share fewer than 30% of their gut bacterial species. What looks like "dysbiosis" by one reference standard may be entirely normal by another.
The Diagnostic Trap
Commercial stool-microbiome tests (16S rRNA sequencing panels) increasingly market themselves as dysbiosis diagnostics. They return colourful reports with diversity scores, bacterial ratios, and "good vs bad bacteria" graphics. Yet no professional gastroenterology, infectious-disease, or microbiology society recommends these tests for clinical decision-making. The American Gastroenterological Association's 2024 clinical practice update explicitly states that microbiome testing lacks validated reference ranges and should not guide therapy outside of Clostridioides difficile infection management.
A Better Framework
Rather than treating dysbiosis as a binary (balanced vs imbalanced), modern microbiome science increasingly focuses on functional capacity — what the microbial community can do, not just which species are present. Metagenomic and metabolomic approaches assess gene content and metabolite production, moving beyond taxonomic lists toward mechanistic understanding. This shift recognises that microbial ecosystems are dynamic, redundant, and context-dependent — and that restoring health likely requires addressing the environment (diet, inflammation, medication) that shapes the community, not simply cataloguing its membership.